Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms

Søren Møller; Nina Kimer; Thit Kronborg; Josephine Grandt; Jens Dahlgaard Hove; Mads Barløse; Lise Lotte Gluud

doi:10.1055/s-0041-1725022

Seminars in Liver Disease, Table of Contents

Semin Liver Dis 2021; 41(03): 235-247
DOI: 10.1055/s-0041-1725022

Review Article

Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms

Søren Møller

¹Department of Clinical Physiology and Nuclear Medicine, Center for Functional and Diagnostic Imaging and Research, Copenhagen University Hospital, Hvidovre, Denmark

²Department of Clinical Medicine, University of Copenhagen, Denmark

,

Nina Kimer

³Gastro Unit, Medical Division, Copenhagen University Hospital Hvidovre, Denmark

⁴Bridge Translational Excellence Program, Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Denmark

,

Thit Kronborg

³Gastro Unit, Medical Division, Copenhagen University Hospital Hvidovre, Denmark

,

Josephine Grandt

³Gastro Unit, Medical Division, Copenhagen University Hospital Hvidovre, Denmark

,

Jens Dahlgaard Hove

¹Department of Clinical Physiology and Nuclear Medicine, Center for Functional and Diagnostic Imaging and Research, Copenhagen University Hospital, Hvidovre, Denmark

⁵Department of Cardiology, Copenhagen University Hospital, Hvidovre, Denmark

,

Mads Barløse

¹Department of Clinical Physiology and Nuclear Medicine, Center for Functional and Diagnostic Imaging and Research, Copenhagen University Hospital, Hvidovre, Denmark

,

Lise Lotte Gluud

²Department of Clinical Medicine, University of Copenhagen, Denmark

³Gastro Unit, Medical Division, Copenhagen University Hospital Hvidovre, Denmark

› Author Affiliations

Abstract

Nonalcoholic fatty liver disease (NAFLD) denotes a condition with excess fat in the liver. The prevalence of NAFLD is increasing, averaging > 25% of the Western population. In 25% of the patients, NAFLD progresses to its more severe form: nonalcoholic steatohepatitis and >25% of these progress to cirrhosis following activation of inflammatory and fibrotic processes. NAFLD is associated with obesity, type 2 diabetes, and the metabolic syndrome and represents a considerable and increasing health burden. In the near future, NAFLD cirrhosis is expected to be the most common cause for liver transplantation. NAFLD patients have an increased risk of developing cardiovascular disease as well as liver-related morbidity. In addition, hepatic steatosis itself appears to represent an independent cardiovascular risk factor. In the present review, we provide an overview of the overlapping mechanisms and prevalence of NAFLD and cardiovascular disease.

Keywords

chronic liver diseases - nonalcoholic steatohepatitis - cirrhosis - atherosclerosis - coronary artery disease - diabetes - obesity

Full Text

References

References
1 Younossi ZM, Henry L, Bush H, Mishra A. Clinical and economic burden of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clin Liver Dis 2018; 22 (01) 1-10
2 Wattacheril J. Extrahepatic manifestations of nonalcoholic fatty liver disease. Gastroenterol Clin North Am 2020; 49 (01) 141-149
3 Jahn D, Rau M, Wohlfahrt J, Hermanns HM, Geier A. Non-alcoholic steatohepatitis: From pathophysiology to novel therapies. Dig Dis 2016; 34 (04) 356-363
4 Chalasani N, Younossi Z, Lavine JE. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67 (01) 328-357
5 Blond E, Disse E, Cuerq C. et al. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral?. Diabetologia 2017; 60 (07) 1218-1222
6 Mundi MS, Velapati S, Patel J, Kellogg TA, Abu Dayyeh BK, Hurt RT. Evolution of NAFLD and its management. Nutr Clin Pract 2020; 35 (01) 72-84
7 Rinella ME, Tacke F, Sanyal AJ, Anstee QM. participants of the AASLD/EASL Workshop. Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD. J Hepatol 2019; 71 (04) 823-833
8 Negro F. Natural history of NASH and HCC. Liver Int 2020; 40 (Suppl. 01) 72-76
9 Loomba R, Wong R, Fraysse J. et al. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data. Aliment Pharmacol Ther 2020; 51 (11) 1149-1159
10 Younossi ZM, Blissett D, Blissett R. et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 2016; 64 (05) 1577-1586
11 Long MT, Gandhi S, Loomba R. Biomarkers of NAFLD and NASH. Metabolism 2020; •••: 154259
12 Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism 2020; 111S: 154170
13 Li AA, Ahmed A, Kim D. Extrahepatic manifestations of nonalcoholic fatty liver disease. Gut Liver 2020; 14 (02) 168-178
14 Lim S, Taskinen MR, Borén J. Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome. Obes Rev 2019; 20 (04) 599-611
15 Dong Y, Li. G. Dong Y. et al. Cardiac abnormalities in patients with nonalcoholic fatty liver disease: Insights from auxiliary examinations. Herz 2019; . Online ahead of print
16 Brouwers MCGJ, Simons N, Stehouwer CDA, Isaacs A. Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality. Diabetologia 2020; 63 (02) 253-260
17 Aron-Wisnewsky J, Vigliotti C, Witjes J. et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol 2020; 17 (05) 279-297
18 Byrne CD, Targher G. What's new in NAFLD pathogenesis, biomarkers and treatment?. Nat Rev Gastroenterol Hepatol 2020; 17 (02) 70-71
19 Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol 2019; 16 (07) 411-428
20 Caussy C, Tripathi A, Humphrey G. et al. A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease. Nat Commun 2019; 10 (01) 1406-09455
21 Danin PE, Anty R, Patouraux S. et al. Non-invasive evaluation of NAFLD with indocyanine green clearance test: a preliminary study in morbidly obese patients undergoing bariatric surgery. Obes Surg 2018; 28 (03) 735-742
22 Castera L, Friedrich-Rust M, Loomba R. Non-invasive assessment of liver disease in patients with NAFLD. Gastroenterology 2019; 156 (05) 1264-1281
23 Adams LA, Chan WK. Noninvasive tests in the assessment of NASH and NAFLD Fibrosis: Now and into the future. Semin Liver Dis 2020; 40 (04) 331-338
24 Carulli L, Zanca G, Schepis F, Villa E. The OMICs window into nonalcoholic fatty liver disease (NAFLD). Metabolites 2019; 9 (02) 25
25 Gastaldelli A, Kozakova M, Højlund K. et al; RISC Investigators. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009; 49 (05) 1537-1544
26 Muthiah MD, Sanyal AJ. Burden of disease due to nonalcoholic fatty liver disease. Gastroenterol Clin North Am 2020; 49 (01) 1-23
27 Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64 (01) 73-84
28 Loomba R, Adams LA. The 20% rule of NASH progression: The natural history of advanced fibrosis and cirrhosis caused by NASH. Hepatology 2019; 70 (06) 1885-1888
29 Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM. Changes in the global burden of chronic liver diseases from 2012 to 2017: The growing impact of nonalcoholic fatty liver disease. Hepatology 2020; 72 (05) 1605-1616
30 McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol 2015; 62 (05) 1148-1155
31 Ballestri S, Lonardo A, Bonapace S, Byrne CD, Loria P, Targher G. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20 (07) 1724-1745
32 Lonardo A, Targher G. Cardiovascular risk in NAFLD: An intimate relationship?. Dig Dis Sci 2020; 65 (06) 1593-1595
33 Allen AM, Therneau TM, Mara KC. et al. Women with nonalcoholic fatty liver disease lose protection against cardiovascular disease: a longitudinal cohort study. Am J Gastroenterol 2019; 114 (11) 1764-1771
34 Mostafa M, Abdelkader A, Evans JJ, Hagen CE, Hartley CP. Fatty liver disease: a practical approach. Arch Pathol Lab Med 2020; 144 (01) 62-70
35 Kleiner DE, Brunt EM, Van Natta M. et al; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41 (06) 1313-1321
36 Itoh S, Yougel T, Kawagoe K. Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis. Am J Gastroenterol 1987; 82 (07) 650-654
37 Sookoian S, Pirola CJ. Systems biology elucidates common pathogenic mechanisms between nonalcoholic and alcoholic-fatty liver disease. PLoS One 2013; 8 (03) e58895
38 Zelber-Sagi S, Lotan R, Shlomai A. et al. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. J Hepatol 2012; 56 (05) 1145-1151
39 Hossain N, Afendy A, Stepanova M. et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7 (11) 1224-1229
40 Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115 (05) 1343-1351
41 Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010; 52 (02) 774-788
42 Marchesini G, Ridolfi V, Nepoti V. Hepatotoxicity of fast food?. Gut 2008; 57 (05) 568-570
43 Polyzos SA, Aronis KN, Kountouras J, Raptis DD, Vasiloglou MF, Mantzoros CS. Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia 2016; 59 (01) 30-43
44 Pappachan JM, Babu S, Krishnan B, Ravindran NC. Non-alcoholic fatty liver disease: a clinical update. J Clin Transl Hepatol 2017; 5 (04) 384-393
45 Choi ES, Kim MK, Song MK. et al. Association between serum irisin levels and non-alcoholic fatty liver disease in health screen examinees. PLoS One 2014; 9 (10) e110680
46 Arias-Loste MT, Ranchal I, Romero-Gómez M, Crespo J. Irisin, a link among fatty liver disease, physical inactivity and insulin resistance. Int J Mol Sci 2014; 15 (12) 23163-23178
47 Nass KJ, van den Berg EH, Faber KN, Schreuder TCMA, Blokzijl H, Dullaart RPF. High prevalence of apolipoprotein B dyslipoproteinemias in non-alcoholic fatty liver disease: the lifelines cohort study. Metabolism 2017; 72: 37-46
48 Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363 (14) 1341-1350
49 Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015; 62 (1, Suppl): S47-S64
50 Arab JP, Arrese M, Shah VH. Gut microbiota in non-alcoholic fatty liver disease and alcohol-related liver disease: current concepts and perspectives. Hepatol Res 2020; 50 (04) 407-418
51 Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol 2020; 72 (03) 558-577
52 Trépo E, Valenti L. Update on NAFLD genetics: from new variants to the clinic. J Hepatol 2020; 72 (06) 1196-1209
53 Sookoian S, Pirola CJ, Valenti L, Davidson NO. Genetic pathways in nonalcoholic fatty liver disease: insights from systems biology. Hepatology 2020; 72 (01) 330-346
54 Gellert-Kristensen H, Richardson TG, Davey SG, Nordestgaard BG, Tybjærg-Hansen A, Stender S. Combined effect of PNPLA3, TM6SF2, and HSD17B13 variants on risk of cirrhosis and hepatocellular carcinoma in the general population. Hepatology 2020
55 Krawczyk M, Liebe R, Lammert F. Towards genetic prediction of non-alcoholic fatty liver disease trajectories: PNPLA3 and beyond. Gastroenterology 2020; 158 (07) 1865-1880.e1
56 Grimaudo S, Pipitone RM, Pennisi G. et al. Association between PNPLA3 rs738409 C>G variant and liver-related outcomes in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2020; 18 (04) 935-944.e3
57 Chandrasekharan K, Alazawi W. Genetics of non-alcoholic fatty liver and cardiovascular disease: implications for therapy?. Front Pharmacol 2020; 10: 1413
58 Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013; 10 (06) 330-344
59 Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008; 49 (04) 608-612
60 Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol 2016; 65 (03) 589-600
61 Kasper P, Martin A, Lang S. et al. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol 2020;
62 Stefan N, Fritsche A, Schick F, Häring HU. Phenotypes of prediabetes and stratification of cardiometabolic risk. Lancet Diabetes Endocrinol 2016; 4 (09) 789-798
63 Ismaiel A, Dumitrascu DL. Cardiovascular risk in fatty liver disease: the liver-heart axis-literature Rrview. Front Med (Lausanne) 2019; 6: 202
64 Choudhary NS, Duseja A. Screening of cardiovascular disease in nonalcoholic fatty liver disease: whom and how?. J Clin Exp Hepatol 2019; 9 (04) 506-514
65 Villanova N, Moscatiello S, Ramilli S. et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005; 42 (02) 473-480
66 Burgess S, Foley CN, Allara E, Staley JR, Howson JMM. A robust and efficient method for Mendelian randomization with hundreds of genetic variants. Nat Commun 2020; 11 (01) 376
67 Dinani A, Sanyal A. Nonalcoholic fatty liver disease: implications for cardiovascular risk. Cardiovasc Endocrinol 2017; 6 (02) 62-72
68 Cusi K. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. Diabetologia 2016; 59: 1112-1120
69 Armstrong MJ, Gaunt P, Aithal GP. et al; LEAN trial team. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016; 387 (10019): 679-690
70 Dulai PS, Singh S, Patel J. et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 2017; 65 (05) 1557-1565
71 Rodriguez-Araujo G. Nonalcoholic fatty liver disease: implications for endocrinologists and cardiologists. Cardiovasc Endocrinol Metab 2020; 9 (03) 96-100
72 Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V. et al. Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study. Gastroenterology 2018; 155 (02) 443-457.e17
73 Ekstedt M, Hagström H, Nasr P. et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015; 61 (05) 1547-1554
74 Taylor RS, Taylor RJ, Bayliss S. et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology 2020; 158 (06) 1611-1625.e12
75 Targher G, Bertolini L, Padovani R. et al. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. J Hepatol 2010; 53 (04) 713-718
76 Treeprasertsuk S, Leverage S, Adams LA, Lindor KD, St Sauver J, Angulo P. The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int 2012; 32 (06) 945-950
77 Byrne CD, Targher G. Liver fat content, non-alcoholic fatty liver disease, and risk of ischaemic heart disease. Eur Heart J 2018; 39 (36) 3398
78 Perseghin G, Lattuada G, De Cobelli F. et al. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology 2008; 47 (01) 51-58
79 Petta S, Argano C, Colomba D. et al. Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease. J Hepatol 2015; 62 (04) 928-933
80 VanWagner LB, Ning H, Lewis CE. et al. Associations between nonalcoholic fatty liver disease and subclinical atherosclerosis in middle-aged adults: the Coronary Artery Risk Development in Young Adults Study. Atherosclerosis 2014; 235 (02) 599-605
81 VanWagner LB. New insights into NAFLD and subclinical coronary atherosclerosis. J Hepatol 2018; 68 (05) 890-892
82 Mirbagheri SA, Rashidi A, Abdi S, Saedi D, Abouzari M. Liver: an alarm for the heart?. Liver Int 2007; 27 (07) 891-894
83 Chang Y, Ryu S, Sung KC. et al. Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung Health Study. Gut 2019; 68 (09) 1667-1675
84 Lautamäki R, Borra R, Iozzo P. et al. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 2006; 291 (02) E282-E290
85 Yilmaz Y, Kurt R, Yonal O. et al. Coronary flow reserve is impaired in patients with nonalcoholic fatty liver disease: association with liver fibrosis. Atherosclerosis 2010; 211 (01) 182-186
86 Boddi M, Tarquini R, Chiostri M. et al. Nonalcoholic fatty liver in nondiabetic patients with acute coronary syndromes. Eur J Clin Invest 2013; 43 (05) 429-438
87 Söderberg C, Stål P, Askling J. et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51 (02) 595-602
88 Baratta F, Pastori D, Angelico F. et al. Nonalcoholic fatty liver disease and fibrosis associated with increased risk of cardiovascular events in a prospective study. Clin Gastroenterol Hepatol 2019; (19) 10
89 Fallo F, Dalla Pozza A, Sonino N. et al. Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. Nutr Metab Cardiovasc Dis 2009; 19 (09) 646-653
90 Bonapace S, Perseghin G, Molon G. et al. Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Care 2012; 35 (02) 389-395
91 Mantovani A, Zoppini G, Targher G, Golia G, Bonora E. Non-alcoholic fatty liver disease is independently associated with left ventricular hypertrophy in hypertensive type 2 diabetic individuals. J Endocrinol Invest 2012; 35 (02) 215-218
92 Mantovani A, Pernigo M, Bergamini C. et al. Nonalcoholic fatty liver disease is independently associated with early left ventricular diastolic dysfunction in patients with type 2 diabetes. PLoS One 2015; 10 (08) e0135329
93 VanWagner LB, Wilcox JE, Ning H. et al. Longitudinal association of non-alcoholic fatty liver disease with changes in myocardial structure and function: the CARDIA Study. J Am Heart Assoc 2020; 9 (04) e014279
94 Mahfood HT, Hamdeh S, Kanmanthareddy A, Alla VM. Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: a systematic review and meta-analysis. Diabetes Metab Syndr 2017; 11 (Suppl. 01) S209-S216
95 Tana C, Ballestri S, Ricci F. et al. Cardiovascular risk in non-alcoholic fatty liver disease: mechanisms and therapeutic implications. Int J Environ Res Public Health 2019; 16 (17) 3104
96 Brea A, Mosquera D, Martín E, Arizti A, Cordero JL, Ros E. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol 2005; 25 (05) 1045-1050
97 Kim HC, Kim DJ, Huh KB. Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome. Atherosclerosis 2009; 204 (02) 521-525
98 Fracanzani AL, Burdick L, Raselli S. et al. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med 2008; 121 (01) 72-78
99 Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol 2008; 49 (04) 600-607
100 Shao C, Ye J, Li F. et al. Early predictors of cardiovascular disease risk in nonalcoholic fatty liver disease: non-obese versus obese patients. Dig Dis Sci 2020; 65 (06) 1850-1860
101 Brunner KT, Pedley A, Massaro JM, Hoffmann U, Benjamin EJ, Long MT. Increasing liver fat is associated with progression of cardiovascular risk factors. Liver Int 2020; 40 (06) 1339-1343
102 VanWagner LB, Terry JG, Chow LS. et al. Nonalcoholic fatty liver disease and measures of early brain health in middle-aged adults: the CARDIA study. Obesity (Silver Spring) 2017; 25 (03) 642-651
103 Oni ET, Agatston AS, Blaha MJ. et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?. Atherosclerosis 2013; 230 (02) 258-267
104 Kovalic AJ, Cholankeril G, Satapathy SK. Nonalcoholic fatty liver disease and alcoholic liver disease: metabolic diseases with systemic manifestations. Transl Gastroenterol Hepatol 2019; 4: 65
105 Zou Y, Li X, Wang C. et al. Association between non-alcoholic fatty liver disease and peripheral artery disease in patients with type 2 diabetes. Intern Med J 2017; 47 (10) 1147-1153
106 Lee YJ, Shim JY, Moon BS. et al. The relationship between arterial stiffness and nonalcoholic fatty liver disease. Dig Dis Sci 2012; 57 (01) 196-203
107 Chung GE, Choi SY, Kim D. et al. Nonalcoholic fatty liver disease as a risk factor of arterial stiffness measured by the cardioankle vascular index. Medicine (Baltimore) 2015; 94 (12) e654
108 Mantovani A, Rigolon R, Mingolla L. et al. Nonalcoholic fatty liver disease is associated with an increased prevalence of distal symmetric polyneuropathy in adult patients with type 1 diabetes. J Diabetes Complications 2017; 31 (06) 1021-1026
109 Tuttolomondo A, Petta S, Casuccio A. et al. Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study. Cardiovasc Diabetol 2018; 17 (01) 28-0670
110 Tsuneto A, Hida A, Sera N. et al. Fatty liver incidence and predictive variables. Hypertens Res 2010; 33 (06) 638-643
111 Wu SJ, Zou H, Zhu GQ. et al. Increased levels of systolic blood pressure within the normal range are associated with significantly elevated risks of nonalcoholic fatty liver disease. Medicine (Baltimore) 2015; 94 (19) e842
112 Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: an update. Metabolism 2016; 65 (08) 1109-1123
113 Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence?. J Hepatol 2018; 68 (02) 335-352
114 Lau K, Lorbeer R, Haring R. et al. The association between fatty liver disease and blood pressure in a population-based cohort study. J Hypertens 2012; 30 (06) 1260-1261
115 Zhang Y, Zhang T, Zhang C. et al. Identification of reciprocal causality between non-alcoholic fatty liver disease and metabolic syndrome by a simplified Bayesian network in a Chinese population. BMJ Open 2015; 5 (09) e008204
116 Ma J, Hwang SJ, Pedley A. et al. Bi-directional analysis between fatty liver and cardiovascular disease risk factors. J Hepatol 2017; 66 (02) 390-397
117 Oikonomou D, Georgiopoulos G, Katsi V. et al. Non-alcoholic fatty liver disease and hypertension: coprevalent or correlated?. Eur J Gastroenterol Hepatol 2018; 30 (09) 979-985
118 Møller S, Bernardi M. Interactions of the heart and the liver. Eur Heart J 2013; 34 (36) 2804-2811
119 Correale M, Tarantino N, Petrucci R. et al. Liver disease and heart failure: back and forth. Eur J Intern Med 2018; 48: 25-34
120 Targher G, Mantovani A, Pichiri I. et al. Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. Clin Sci (Lond) 2013; 125 (06) 301-309
121 Anstee QM, Mantovani A, Tilg H, Targher G. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2018; 15 (07) 425-439
122 Sinner MF, Wang N, Fox CS. et al. Relation of circulating liver transaminase concentrations to risk of new-onset atrial fibrillation. Am J Cardiol 2013; 111 (02) 219-224
123 Targher G, Valbusa F, Bonapace S. et al. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS One 2013; 8 (02) e57183
124 Mantovani A, Dauriz M, Sandri D. et al. Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: an updated meta-analysis. Liver Int 2019; 39 (04) 758-769
125 Mahfouz RA, Gouda M, Galal I, Ghareb MS. Interatrial septal fat thickness and left atrial stiffness are mechanistic links between nonalcoholic fatty liver disease and incident atrial fibrillation. Echocardiography 2019; 36 (02) 249-256
126 Mantovani A, Rigolon R, Pichiri I. et al. Nonalcoholic fatty liver disease is associated with an increased risk of heart block in hospitalized patients with type 2 diabetes mellitus. PLoS One 2017; 12 (10) e0185459
127 Targher G, Valbusa F, Bonapace S. et al. Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes. Nutr Metab Cardiovasc Dis 2014; 24 (06) 663-669
128 Hung CS, Tseng PH, Tu CH. et al. Nonalcoholic fatty liver disease is associated with QT prolongation in the general population. J Am Heart Assoc 2015;4(07):
129 Mantovani A, Rigamonti A, Bonapace S. et al. Nonalcoholic fatty liver disease is associated with ventricular arrhythmias in patients with type 2 diabetes referred for clinically indicated 24-hour Holter monitoring. Diabetes Care 2016; 39 (08) 1416-1423
130 Newton JL, Pairman J, Wilton K, Jones DE, Day C. Fatigue and autonomic dysfunction in non-alcoholic fatty liver disease. Clin Auton Res 2009; 19 (06) 319-326
131 Liu YC, Hung CS, Wu YW. et al. Influence of non-alcoholic fatty liver disease on autonomic changes evaluated by the time domain, frequency domain, and symbolic dynamics of heart rate variability. PLoS One 2013; 8 (04) e61803
132 Ozveren O, Dogdu O, Sengul C. et al. Deterioration of heart rate recovery index in patients with non-alcoholic fatty liver disease (NAFLD). Med Sci Monit 2014; 20: 1539-1543
133 Houghton D, Zalewski P, Hallsworth K. et al. The degree of hepatic steatosis associates with impaired cardiac and autonomic function. J Hepatol 2019; 70 (06) 1203-1213
134 Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut 2020; 69 (09) 1691-1705
135 European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64 (06) 1388-1402
136 Fedchuk L, Nascimbeni F, Pais R, Charlotte F, Housset C, Ratziu V. LIDO Study Group. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2014; 40 (10) 1209-1222
137 Ratziu V, Charlotte F, Heurtier A. et al; LIDO Study Group. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128 (07) 1898-1906
138 Kleiner DE, Brunt EM. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis 2012; 32 (01) 3-13
139 Nascimbeni F, Bedossa P, Fedchuk L. et al; LIDO (Liver Injury in Diabetes and Obesity) Study Group. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease. J Hepatol 2020; 72 (05) 828-838
140 Guha IN, Parkes J, Roderick P. et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008; 47 (02) 455-460
141 McPherson S, Anstee QM, Henderson E, Day CP, Burt AD. Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?. Eur J Gastroenterol Hepatol 2013; 25 (06) 652-658
142 Thiele M, Kjaergaard M, Thielsen P, Krag A. Contemporary use of elastography in liver fibrosis and portal hypertension. Clin Physiol Funct Imaging 2017; 37 (03) 235-242
143 Younossi ZM, Loomba R, Anstee QM. et al. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology 2018; 68 (01) 349-360
144 Preiss D, Kristensen SL. The new pooled cohort equations risk calculator. Can J Cardiol 2015; 31 (05) 613-619
145 Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut 2017; 66 (01) 180-190
146 Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 2017; 66 (06) 1138-1153
147 Goff Jr DC, Lloyd-Jones DM, Bennett G. et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129 (25, Suppl 2): S49-S73
148 Piepoli MF, Hoes AW, Agewall S. et al; Authors/Task Force Members, Additional Contributor: Simone Binno (Italy), Document Reviewers. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol 2016; 23 (11) NP1-NP96
149 Lloyd-Jones DM, Braun LT, Ndumele CE. et al. Use of risk assessment tools to “a Guide” decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American Heart Association and American College of Cardiology. J Am Coll Cardiol 2019; 73 (24) 3153-3167
150 Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol 2017; 67 (04) 829-846
151 Asbaghi O, Choghakhori R, Ashtary-Larky D, Abbasnezhad A. Effects of the Mediterranean diet on cardiovascular risk factors in non-alcoholic fatty liver disease patients: a systematic review and meta-analysis. Clin Nutr ESPEN 2020; 37: 148-156
152 Aminian A, Zajichek A, Arterburn DE. et al. Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity. JAMA 2019; 322 (13) 1271-1282
153 Lassailly G, Caiazzo R, Ntandja-Wandji LC. et al. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis. Gastroenterology 2020; 159 (04) 1290-1301.e5
154 El-Agroudy NN, Kurzbach A, Rodionov RN. et al. Are lifestyle therapies effective for NAFLD treatment?. Trends Endocrinol Metab 2019; 30 (10) 701-709
155 Kothari S, Dhami-Shah H, Shah SR. Antidiabetic drugs and statins in nonalcoholic fatty liver disease. J Clin Exp Hepatol 2019; 9 (06) 723-730
156 van den Berg EH, Wolters AAB, Dullaart RPF. et al. Prescription of statins in suspected non-alcoholic fatty liver disease and high cardiovascular risk, a population-based study. Liver Int 2019; 39 (07) 1343-1354
157 Tikkanen MJ, Fayyad R, Faergeman O. et al; IDEAL Investigators. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol 2013; 168 (04) 3846-3852
158 Hyogo H, Yamagishi S, Maeda S, Kimura Y, Ishitobi T, Chayama K. Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property. Dig Liver Dis 2012; 44 (06) 492-496
159 Pastori D, Polimeni L, Baratta F, Pani A, Del Ben M, Angelico F. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis 2015; 47 (01) 4-11
160 Dongiovanni P, Petta S, Mannisto V. et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol 2015; 63 (03) 705-712
161 Nascimbeni F, Aron-Wisnewsky J, Pais R. et al; LIDO study Group. Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease. BMJ Open Gastroenterol 2016; 3 (01) e000075
162 Athyros VG, Alexandrides TK, Bilianou H. et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An expert panel statement. Metabolism 2017; 71: 17-32
163 Kim RG, Loomba R, Prokop LJ, Singh S. Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2017; 15 (10) 1521-1530.e8
164 Bril F, Portillo Sanchez P, Lomonaco R. et al. Liver safety of statins in prediabetes or T2DM and nonalcoholic steatohepatitis: post hoc analysis of a randomized trial. J Clin Endocrinol Metab 2017; 102 (08) 2950-2961
165 Sigler MA, Congdon L, Edwards KL. An evidence-based review of statin use in patients with nonalcoholic fatty liver disease. Clin Med Insights Gastroenterol 2018; 11: 1179552218787502
166 Pockros PJ, Fuchs M, Freilich B. et al. CONTROL: a randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients. Liver Int 2019; 39 (11) 2082-2093
167 Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010; 52 (01) 79-104
168 Sanyal AJ, Chalasani N, Kowdley KV. et al; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362 (18) 1675-1685
169 Eguchi Y, Kitajima Y, Hyogo H. et al; Japan Study Group for NAFLD (JSG-NAFLD). Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). Hepatol Res 2015; 45 (03) 269-278
170 Petit JM, Cercueil JP, Loffroy R. et al. Effect of Liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: the Lira-NAFLD study. J Clin Endocrinol Metab 2017; 102 (02) 407-415
171 Cusi K. Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus. Gut 2018; 67 (07) 1371-313958
172 Khoo J, Hsiang JC, Taneja R. et al. Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease. Liver Int 2019; 39 (05) 941-949
173 Newsome PN, Buchholtz K, Cusi K. et al; NN9931-4296 Investigators. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 2021; 384 (12) 1113-1124
174 Kristensen SL, Rørth R, Jhund PS. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 2019; 7 (10) 776-785
175 Teshome G, Ambachew S, Fasil A, Abebe M. Efficacy of glucagon-like peptide-1 analogs in nonalcoholic fatty liver disease: a systematic review. Hepat Med 2020; 12: 139-151